Saketh R Guntupalli
Overview
Explore the profile of Saketh R Guntupalli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Res
. 2024 Aug;
22(12):1117-1127.
PMID: 39136655
Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an...
2.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Ther
. 2024 Jun;
:OF1-OF16.
PMID: 38863225
Despite the success of poly-ADP-ribose polymerase inhibitors (PARPi) in the clinic, high rates of resistance to PARPi presents a challenge in the treatment of ovarian cancer, thus it is imperative...
3.
Floyd J, Porragas-Paseiro H, Nguyen C, Moroney M, Mastroyannis S, Guntupalli S
Ann Surg Oncol
. 2024 May;
31(8):5102-5110.
PMID: 38780692
Background: Venous thromboembolism is a preventable complication of gynecologic cancer surgery that leads to postoperative morbidity and mortality. This study compared apixaban with enoxaparin to identify whether apixaban had the...
4.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
Mol Cancer Ther
. 2024 May;
PMID: 38714351
Despite the success of Poly-ADP-ribose polymerase inhibitors (PARPi) in the clinic, high rates of resistance to PARPi presents a challenge in the treatment of ovarian cancer, thus it is imperative...
5.
Dexter J, Brubaker L, Bitler B, Goff B, Menon U, Moore K, et al.
Gynecol Oncol Rep
. 2024 Apr;
53:101376.
PMID: 38590930
Early diagnosis and screening of ovarian cancer remain significant challenges to improving patient outcomes. There is an urgent need to implement both established and modern strategies to address the "early...
6.
Helm E, Guntupalli S
Gynecol Oncol Rep
. 2024 Mar;
52:101352.
PMID: 38495801
•Cardiac metastasis is a rare complication of squamous cell carcinoma of the cervix.•Biologic agents may be a useful treatment modality for cardiac metastasis of squamous cell carcinoma of the cervix.•Multidisciplinary...
7.
Davies K, Smith L, Guimaraes-Young A, Corr B, Fisher C, Guntupalli S, et al.
Int J Gynecol Pathol
. 2023 Nov;
43(4):335-348.
PMID: 37922951
Based on findings from The Cancer Genome Atlas and the Proactive Molecular Risk Classifier for Endometrial Cancer algorithm, endometrial carcinoma can now be stratified into 4 prognostically distinct subgroups based...
8.
Navi B, Zhang C, Kaiser J, Liao V, Cushman M, Kasner S, et al.
Eur Heart J Qual Care Clin Outcomes
. 2023 Sep;
10(4):345-356.
PMID: 37757472
Background And Aims: Most cancer patients require surgery for diagnosis and treatment. This study evaluated whether cancer is a risk factor for perioperative arterial ischaemic events. Methods: The primary cohort...
9.
Guntupalli S, Spinosa D, Wethington S, Eskander R, Khorana A
BMJ
. 2023 Jun;
381:e072715.
PMID: 37263632
Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients with cancer. Venous thromboembolism, which includes both deep vein thrombosis and pulmonary embolism, affects a sizable...
10.
Nguyen L, Watson Z, Ortega R, Woodruff E, Jordan K, Iwanaga R, et al.
bioRxiv
. 2023 Mar;
PMID: 36865165
Euchromatic histone lysine methyltransferases 1 and 2 (EHMT1/2), which catalyze demethylation of histone H3 lysine 9 (H3K9me2), contribute to tumorigenesis and therapy resistance through unknown mechanisms of action. In ovarian...